More on Less

In April of last year, I wrote about the first release of recommendations from the American Board on Internal Medicine Foundation in conjunction with nine medical societies as part of a campaign: Choosing Wisely. The campaign aims to draw attention to and call into question commonly ordered tests like chest x-rays before surgery, frequently performed procedures like colonoscopies, and frequently prescribed treatments like antibiotics for upper respiratory infections. The campaign is directed to clinicians and patients with both audiences asked to consider the evidence for not doing select tests and procedures in specific circumstances where the evidence supports not doing the test or procedure or treatment.

Fast forward 10 months. The ABIM Foundation has released 90 more recommendations in conjunction with medical specialty societies for physicians, other clinicians, and patients/consumers asking us to consider the evidence and to choose wisely. We should applaud the ABIM Foundation, the National Physician Alliance, Consumer Reports and the dozens of medical specialty societies that have assumed the mantle of leadership to bring this information to health care professionals and to consumers in clear, crisp, and concise statements.

Meetings

HealthIMPACT Southeast Tampa, FL January 23, 2015

Our other journal

P&T Journal for November 2014

FEATURES

LETTER TO THE EDITOR

Medications for Parkinson’s Disease

PERSPECTIVE

The Changing Roles of P&T Committees

Epilepsy Management: Newer Agents, Unmet Needs, and Future Treatment Strategies

PIPELINE PLUS

Modest Growth Seen in Epilepsy Market

MEETING HIGHLIGHTS

European Society of Cardiology and Transcatheter Cardiovascular Therapeutics

BOOK REVIEW

“Generic: The Unbranding of Modern Medicine,” by Jeremy A. Greene, MD, PhD

DEPARTMENTSMEDICATION ERRORS

Misadministration of IV Insulin Associated With Dose Measurement And Hyperkalemia Treatment

PRESCRIPTION: WASHINGTON

FDA’s Proposed 503B Draft Compounding Guidance Raises Concerns of All Kinds

New Drugs/Drug News

Pharmaceutical Approval Update

DRUG FORECAST

Riociguat (Adempas): a Novel Agent For the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

Leave a Comment